The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Targeting Toll-like receptors: emerging therapeutics?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“A recent study showed that the TLR4 signalling pathway can mediate such a signa”
BackgroundAIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., & Alnemri, E. S. (2009) · Nature · doi:10.1038/nature07710 · Cited by 1,831
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Phototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453
Burguillos, M. A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M. J., Osman, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.012 · Cited by 365
Sameer, A. S., & Nissar, S. (2021) · BioMed Research International · doi:10.1155/2021/1157023 · Cited by 323
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
“acid sensing TLRs, such as TLR3, require modified oligonucleotides.(87) Indeed, besides natural dsRNA molecules, TLR3 also recognizes synthetic dsRNA analogs,(48) such as polyriboinosinic:polyribocytidylic acid (polyI:C),(92) polyadenylic:polyuridylic acid (polyA:U),(93) polyriboinosinic-polyribocytidylic acidpolylysi…”
BackgroundDysregulation of human Toll-like receptor function in aging
Shaw, A. C., Panda, A., Joshi, S. R., Qian, F., Allore, H. G., & Montgomery, R. R. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.10.007 · Cited by 215
Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development
Zurolo, E., Iyer, A., Maroso, M., Carbonell, C., Anink, J. J., Ravizza, T., Fluiter, K., Spliet, W. G. M., van Rijen, P. C., Vezzani, A., et al. (2011) · Brain · doi:10.1093/brain/awr032 · Cited by 207
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits
Chevrier, N., Mertins, P., Artyomov, M. N., Shalek, A. K., Iannacone, M., Ciaccio, M. F., Gat-Viks, I., Tonti, E., DeGrace, M. M., Clauser, K. R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.022 · Cited by 179
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164
The Toll-like receptor gene family is integrated into human DNA damage and p53 networks
Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001360 · Cited by 148
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131
Liu, J., Han, C., Xie, B., Wu, Y., Liu, S., Chen, K., Xia, M., Zhang, Y., Song, L., Li, Z., et al. (2014) · Nature Immunology · doi:10.1038/ni.2898 · Cited by 128
Li, W., Wang, K., Liu, Y., Wu, H., He, Y., Li, C., Wang, Q., Su, X., Yan, S., Su, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912933 · Cited by 106
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Al-Riyami, L., Pineda, M. A., Rzepecka, J., Huggan, J. K., Khalaf, A. I., Suckling, C. J., Scott, F. J., Rodgers, D. T., Harnett, M. M., & Harnett, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401251p · Cited by 94
Toll-like receptor agonists: a patent review (2011 - 2013)
Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68
VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis
Horak, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.583237 · Cited by 51
Recent Advances in Studying Toll-like Receptors with the Use of Computational Methods
Bzówka, M., Bagrowska, W., & Góra, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00419 · Cited by 34
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Piscianz, E., Cuzzoni, E., Sharma, R., Tesser, A., Sapra, P., & Tommasini, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170911162331 · Cited by 15
Metadata
- Authors
- Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-04
- Volume
- 9
- Issue
- 4
- Pages
- 293-307
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2013469022
- Cited by
- 886
- References
- 5
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
